All In Biotech

Drug Trial Radar · NCT06665100

PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)

Efficacy and Safety of PUL-042 Inhalation Solution in Reducing Lower Respiratory Tract Complications in Patients With Hematologic Malignancies and Recipients of Hematopoietic Stem Cell Transplantation (HSCT) With Documented Viral Infections With PIV, hMPV or RSV

Last checked: Nov 19, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Jun 27, 2025

Primary completion

Apr 2027

Study completion May 2027

Sponsor

Lead sponsor
Pulmotect, Inc.Industry
Sponsor type
Industry
Collaborators
Cancer Prevention Research Institute of Texas
First posted
Oct 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this research study is to try to see whether an experimental drug, PUL 042 Inhalation Solution (PUL 042), is effective in reducing the severity of lung infections in patients with hematologic malignancies and recipients of hematopoietic stem cell transplantation with documented viral infections due to PIV, hMPV, or RSV. PUL-042 or a placebo will be administered 3 times over a 6-day period. The total duration of the study will be approximately 30 days.

Conditions

  • Hematologic Malignancies
  • Hematopoietic Stem Cell Transplant (HSCT)

Interventions

  • PUL-042Drug

    Pam2 : ODN (PUL-042) PUL-042 Inhalation Solution

  • PlaceboDrug

    Sterile Saline for Inhalation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of PUL-042 Inhalation Solution on Lower Respiratory Tract Complications (LRTC)Time frame: 28 days

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California · Recruiting

  • Northside Hospital

    Atlanta, Georgia · Recruiting

  • Johns Hopkins Hospital

    Baltimore, Maryland · Recruiting

  • Brigham and Women's Hospital

    Boston, Massachusetts · Recruiting

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • University of Minnesota

    Minneapolis, Minnesota · Recruiting

  • John Theurer Cancer Center

    Hackensack, New Jersey · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Active not recruiting

  • Lineberger Cancer

    Chapel Hill, North Carolina · Recruiting

  • OU Health Physicians - Infectious Disease Clinic

    Oklahoma City, Oklahoma · Recruiting

  • University of Texas MD Anderson MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.